KLK3 and prostate cancer: In addition, the sensitivity analysis, split by follow-up time, showed slight increases in hazard ratios for the first 2 years for prostate cancer for all models, even when adjusting for 5-ɑ reductase inhibitor exposure and PSA testing intensity, likely due to residual detection bias.